Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CET

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to nymonitoring@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04:39p JOHNSON & JOHNSON : Innovation launches Singapore QuickFire Challenge Competitio..
03:17p AT&T and Johnson & Johnson Pull Ads From YouTube
01:43p OPPORTUNISM KNOCKS : Marketers and media take on Google
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
01:35a HOLOGIC : Global in-Vitro Diagnostics (IVD) Market-Danaher, Hologic, Alere, BD, ..
01:19a JOHNSON & JOHNSON : Global First Aid Kit Market-Honeywell, Wah Lee, Yunnan Baiya..
03/23 JOHNSON & JOHNSON : Investigators at Johnson & Johnson Report New Data on Schizo..
03/23 JOHNSON & JOHNSON : Thicon announces completion of acquisition of torax medical,..
03/23 JOHNSON & JOHNSON : Risperdal Lawsuits Contribute to Johnson & Johnson's Growing..
03/23 JOHNSON & JOHNSON : J&J pulls ads from YouTube over 'offensive' videos
More news
Sector news : Pharmaceuticals - NEC
03:42p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:18a RETIREES : How To Protect The Principal Of Your Dividend Portfolio
09:51a European advisory committee backs J & J's Elmiron for bladder pain syndrome
06:58a WALL STREET BREAKFAST : Art Of The Healthcare Deal
02:44a YouTube ad exodus continues
03/23 THE THREAT AND RISK OF RISING INTERE : Separating Fact From Fiction
Advertisement
Financials ($)
Sales 2017 74 632 M
EBIT 2017 23 011 M
Net income 2017 17 928 M
Finance 2017 21 362 M
Yield 2017 2,66%
P/E ratio 2017 19,07
P/E ratio 2018 17,80
EV / Sales 2017 4,29x
EV / Sales 2018 4,03x
Capitalization 341 301 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 126 $
Spread / Average Target 0,31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.49%173 740
SANOFI7.63%115 841
More Results